Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURMOUNT-J: Once-weekly tirzepatide for obesity disease in Japanese participants
jRCT2031210044Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of tirzepatide in obesity (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of participants who achieve at least 5% body weight reduction and Percent change in body weight. Started May 2021; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on jRCT2031210044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210044.